Table 1.

The main characteristics of the studies on the safety and efficacy of COVID-19 vaccine in children and adolescents.

Study	Population	Study Type	Vaccine	All Person	Controls	Vaccine Efficacy (95%CI)	The Most Common Adverse Events after First and Second Dose
Frenck et al. [24]	5–11 years	Randomized controlled trial	BNT162b2 mRNA	2260	1129	100% (95% CI, 78.1 to 100)	-injection site reactions (86%/79%) -fatigue (60%/66%) -headache (55%/65%)
Hause et al. [25]	12–17 years	observational study	BNT162b2 mRNA	66,550	/	/	-injection site reactions (63.9%/62.4%) -fatigue (27.4%/44.6%) -headache (25.2%/43.7%)
Freedman et al. [26]	12–15 years	observational study	BNT162b2 mRNA	187,707	/	91.5% (95% CI 88.2–93.9%	/
Ali et al. [27]	12–17 years	Randomized controlled trial	mRNA-1273	3732	1243	98.8(95%CI = 97.0 to 99.7)	-injection site reactions (93.1%/92.4%) -fatigue (47.9%/67.8%) -headache (38.5%30.2%%)
Walter et al. [28]	5–11 years	Randomized controlled trial	BNT162b2 mRNA	2268	750	90.7% (95% CI, 67.7–98.3)	-injection site reactions -Fatigue -Headache